Finerenone is the first mineralocorticoid receptor (MR) antagonist to demonstrate definitive cardiovascular benefits in a Phase III study in patients with heart failure (HF) with a left ventricular ejection fraction (LVEF) of ?40%
MyClad is a global Phase III study evaluating the efficacy and safety of cladribine capsules for the treatment of generalized Myasthenia Gravis (gMG)
H.coagulans is, unlike other general lactobacillus, characterized by spore formation, giving it resistance to acid and heat
Biocon Biologics earlier announced a settlement agreement in the United States for a Bmab 1200 launch no later than February 22, 2025
Ordspono is Regeneron’s first approved bispecific antibody and will provide an off-the-shelf option that can be administered in the out-patient setting, with hope for complete remission
New analyses, including presentations on mavacamten, apixaban and milvexian, further solidify the company's strength and expertise as a leader in cardiovascular diseases
Winrevair is the first activin signaling inhibitor therapy for PAH approved in Europe
PiaSky advances C5 inhibition through innovative recycling technology, which enables its monthly SC administration
Honeywell Quality Management Review helps manufacturers boost efficiency and quality compliance
Approval based on MIRACLE Phase III trial demonstrating a significant and clinically meaningful reduction in asthma exacerbations and improvement in asthma symptom control
Subscribe To Our Newsletter & Stay Updated
